Literature DB >> 16449615

Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment.

Lee S Cohen1, Lori L Altshuler, Bernard L Harlow, Ruta Nonacs, D Jeffrey Newport, Adele C Viguera, Rita Suri, Vivien K Burt, Victoria Hendrick, Alison M Reminick, Ada Loughead, Allison F Vitonis, Zachary N Stowe.   

Abstract

CONTEXT: Pregnancy has historically been described as a time of emotional well-being, providing "protection" against psychiatric disorder. However, systematic delineation of risk of relapse in women who maintain or discontinue pharmacological treatment during pregnancy is necessary.
OBJECTIVE: To describe risk of relapse in pregnant women who discontinued antidepressant medication proximate to conception compared with those who maintained treatment with these medications. DESIGN, SETTING, AND PATIENTS: A prospective naturalistic investigation using longitudinal psychiatric assessments on a monthly basis across pregnancy; a survival analysis was conducted to determine time to relapse of depression during pregnancy. A total of 201 pregnant women were enrolled between March 1999 and April 2003 from 3 centers with specific expertise in the treatment of psychiatric illness during pregnancy. The cohort of women was recruited from (1) within the hospital clinics, (2) self-referral via advertisements and community outreach detailing the study, and (3) direct referrals from the community. Participants were considered eligible if they (1) had a history of major depression prior to pregnancy, (2) were less than 16 weeks' gestation, (3) were euthymic for at least 3 months prior to their last menstrual period, and (4) were currently or recently (<12 weeks prior to last menstrual period) receiving antidepressant treatment. Of the 201 participants, 13 miscarried, 5 electively terminated their pregnancy, 12 were lost to follow-up prior to completion of pregnancy, and 8 chose to discontinue participation in the study. MAIN OUTCOME MEASURE: Relapse of major depression defined as fulfilling Structured Clinical Interview for DSM-IV [Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition] Diagnosis (SCID) criteria.
RESULTS: Among the 201 women in the sample, 86 (43%) experienced a relapse of major depression during pregnancy. Among the 82 women who maintained their medication throughout their pregnancy, 21 (26%) relapsed compared with 44 (68%) of the 65 women who discontinued medication. Women who discontinued medication relapsed significantly more frequently over the course of their pregnancy compared with women who maintained their medication (hazard ratio, 5.0; 95% confidence interval, 2.8-9.1; P<.001).
CONCLUSIONS: Pregnancy is not "protective" with respect to risk of relapse of major depression. Women with histories of depression who are euthymic in the context of ongoing antidepressant therapy should be aware of the association of depressive relapse during pregnancy with antidepressant discontinuation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16449615     DOI: 10.1001/jama.295.5.499

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  212 in total

1.  Quality assessment of observational studies in psychiatry: an example  from perinatal psychiatric research.

Authors:  L E Ross; S Grigoriadis; L Mamisashvili; G Koren; M Steiner; C-L Dennis; A Cheung; P Mousmanis
Journal:  Int J Methods Psychiatr Res       Date:  2011-12       Impact factor: 4.035

2.  Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.

Authors:  Khaled Abduljalil; Penny Furness; Trevor N Johnson; Amin Rostami-Hodjegan; Hora Soltani
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

Review 3.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

4.  Neonatal seizures on EEG after in utero exposure to venlafaxine.

Authors:  Chris J C Hoppenbrouwers; Jacob Bosma; Hanneke J M B Wennink; Antonius A J Hilgevoord; Marion Heres; Adriaan Honig
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

5.  Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy.

Authors:  David M Haas; Jamie L Renbarger; Scott Denne; Mahmoud S Ahmed; Thomas Easterling; Karen Feibus; Eric M Meslin; Gideon Koren; Anne Zajicek; Wayne R Snodgrass; David A Flockhart
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

6.  Use of antidepressants during pregnancy and the risk of spontaneous abortion.

Authors:  Hamid Reza Nakhai-Pour; Perrine Broy; Anick Bérard
Journal:  CMAJ       Date:  2010-05-31       Impact factor: 8.262

Review 7.  Pharmacogenetics and individualizing drug treatment during pregnancy.

Authors:  David M Haas
Journal:  Pharmacogenomics       Date:  2014-01       Impact factor: 2.533

Review 8.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

9.  A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight.

Authors:  Hsiang Huang; Shane Coleman; Jeffrey A Bridge; Kimberly Yonkers; Wayne Katon
Journal:  Gen Hosp Psychiatry       Date:  2013-10-02       Impact factor: 3.238

10.  Prepregnancy depressive symptoms and preterm birth in the Black Women's Health Study.

Authors:  Ghasi S Phillips; Lauren A Wise; Janet W Rich-Edwards; Meir J Stampfer; Lynn Rosenberg
Journal:  Ann Epidemiol       Date:  2010-01       Impact factor: 3.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.